ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO657

Persistent Proteinuria Associated with CUBN Variants in Korean Children

Session Information

  • Pediatric Nephrology - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1900 Pediatric Nephrology


  • Choi, Yun Young, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)
  • Choi, Naye, Seoul National University Hospital, Jongno-gu, Korea (the Republic of)
  • Min, Jeesu, Chungnam National University Sejong Hospital, Sejong, Korea (the Republic of)
  • Park, Eujin, Korea University Guro Hospital, Seoul, Korea (the Republic of)
  • Ahn, Yo Han, Seoul National University Hospital, Jongno-gu, Korea (the Republic of)
  • Kang, Hee Gyung, Seoul National University Hospital, Jongno-gu, Korea (the Republic of)
  • Lee, Hyun Kyung, Kangwon National University Hospital, Chuncheon, Kangwon, Korea (the Republic of)

Persistent proteinuria is a risk factor of progression for chronic kidney disease (CKD). However, the recent discovery suggests that not all proteinuria is damaging. CUBN, encoding the membrane glycoprotein cubilin, forms cubilin-amnionless-megalin complex that is responsible for the receptor-mediated endocytosis of albumin in the proximal tubules. A defect of cubilin decreases albumin reuptake, consequently resulting in proteinuria. Interestingly, variants located at the N-terminal of CUBN result in severe proteinuria and megaloblastic anemia, whereas variants at the C-terminal are associated with benign, isolated proteinuria.

Case Description

Here, we report 6 Korean patients (M:F=3:3) presented with persistent proteinuria with homozygous or compound heterozyous C-terminal CUBN variants. All patients presented with incidentally found isolated asymptomatic proteinuria, at their median age of 5 years (range 18 months ~ 9years). Their mean urine protein creatinine ratios was 1.13 (range 0.94 ~ 1.5) mg/mg at presentation and laboratory findings were unremarkable at presentation for eGFR, serum albumin, lipid, hemoglobin, urine 2-microglobulin and N-acetyl-beta-D-glucosaminidase. None had hypertension, and kidney ultrasound was normal. Two patients underwent kidney biopsy, which revealed non-specific findings. Their median follow-up duration was 4 years (range 6 months ~ 12 years) , median age at the last follow-up was 8.5 years (range 2 years ~21 years) and the amount of proteinuria and the kidney function did not change significantly over time regardless of renin-angiotensin-aldosterone system (RAS) inhibition with mean urine protein creatinine ratio at the last follow up of 0.965 (range 0.75 ~ 1.175).


These cases are similar to previously reported cases, indicating that asymptomatic subnephrotic range proteinuria patients should be suspected of C-terminal variants of CUBN gene. There are still debates on whether CUBN C-terminal mutation is truly benign proteinuria, and whether clinicians should treat these patients with RASi.